Status:
UNKNOWN
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases
Lead Sponsor:
Lund University Hospital
Conditions:
Radiotherapy
Brain Metastases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metast...
Eligibility Criteria
Inclusion
- Patients prescribed stereotactic radiation therapy to the brain, where MRI imaging is included in the treatment preparations.
- Cohesive remaining solid tumor component of ≥10mm.
- Age ≥18 years.
- World Health Organisation (WHO) performance status 0-1.
Exclusion
- Inability to decide for oneself on participation in the study.
- Inability to understand the Swedish language.
- Metastases close to the base of the skull.
- Contraindications to conducting an MRI examination.
- Contraindications to obtaining contrast media during MRI examination.
- Expected survival less than 6 months.
- Previous radiation treatment to the same site in the brain, i.e. current treatment is a rope radiation.
- \-
Key Trial Info
Start Date :
December 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04700748
Start Date
December 28 2020
End Date
December 31 2023
Last Update
January 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lund University Hospital
Lund, Sweden, 221 85